Company intelligence / Profile preview
Prospect Therapeutics
Wellesley Hills (liquidation contact); HQ in Woburn, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Prospect Therapeutics developed GCS-100, a carbohydrate molecule targeting galectin-3 for cancer treatment. GCS-100 reached Phase 2 trials (notably in leukemia and lymphoma), but the company ceased operations and assets were liquidated. Initial clinical results suggested inhibition of tumor angiogenesis and possible activity in hematologic cancers[3][4][5].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeCarbohydrate molecule
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Prospect Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prospect Therapeutics.